Title
|
Journal
|
Published year
|
Total citation
(n)
|
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
|
SCIENCE TRANSLATIONAL MEDICINE
|
2011
|
1,052
|
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
|
LANCET
|
2015
|
954
|
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|
SCIENCE TRANSLATIONAL MEDICINE
|
2014
|
935
|
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
|
JOURNAL OF CLINICAL ONCOLOGY
|
2015
|
644
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
|
JOURNAL OF CLINICAL INVESTIGATION
|
2011
|
522
|
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
|
SCIENCE TRANSLATIONAL MEDICINE
|
2015
|
484
|
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
|
BLOOD
|
2011
|
465
|
CD19 CAR-T cells of defined CD4(+): CD8(+) composition in adult B cell ALL patients
|
JOURNAL OF CLINICAL INVESTIGATION
|
2016
|
424
|
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|
NEW ENGLAND JOURNAL OF MEDICINE
|
2017
|
380
|
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|
NEW ENGLAND JOURNAL OF MEDICINE
|
2018
|
347
|
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
|
BLOOD
|
2014
|
331
|
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
|
CANCER IMMUNOLOGY RESEARCH
|
2014
|
322
|
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
|
NATURE MEDICINE
|
2015
|
308
|
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|
NEW ENGLAND JOURNAL OF MEDICINE
|
2016
|
283
|
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
|
CLINICAL CANCER RESEARCH
|
2013
|
280
|
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
|
JOURNAL OF CLINICAL ONCOLOGY
|
2015
|
279
|
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
|
BLOOD
|
2013
|
269
|
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
|
MOLECULAR THERAPY
|
2013
|
263
|
Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
|
BLOOD
|
2012
|
260
|
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
|
NATURE REVIEWS CLINICAL ONCOLOGY
|
2016
|
258
|
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
|
NATURE
|
2017
|
249
|
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8(+) and CD4(+) CD19-specific chimeric antigen receptor-modified T cells
|
SCIENCE TRANSLATIONAL MEDICINE
|
2016
|
249
|
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
|
SCIENCE TRANSLATIONAL MEDICINE
|
2012
|
249
|
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
|
BLOOD
|
2015
|
239
|
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
|
NEW ENGLAND JOURNAL OF MEDICINE
|
2018
|
225
|
Toxicities of chimeric antigen receptor T cells: recognition and management
|
BLOOD
|
2016
|
222
|
Multiple Injections of Electroporated Autologous T Cells Expressing a Chimeric Antigen Receptor Mediate Regression of Human Disseminated Tumor
|
CANCER RESEARCH
|
2010
|
219
|
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
|
NATURE REVIEWS CLINICAL ONCOLOGY
|
2013
|
215
|
The Principles of Engineering Immune Cells to Treat Cancer
|
CELL
|
2017
|
209
|
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
|
SCIENCE TRANSLATIONAL MEDICINE
|
2017
|
206
|
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
|
CANCER IMMUNOLOGY RESEARCH
|
2013
|
206
|
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
|
NATURE REVIEWS CLINICAL ONCOLOGY
|
2018
|
187
|
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
|
CANCER DISCOVERY
|
2016
|
185
|
Toxicity and management in CAR T-cell therapy
|
MOLECULAR THERAPY-ONCOLYTICS
|
2016
|
182
|
Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
|
CLINICAL CANCER RESEARCH
|
2013
|
182
|
Design and development of therapies using chimeric antigen receptor-expressing T cells
|
IMMUNOLOGICAL REVIEWS
|
2014
|
181
|
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
|
BLOOD
|
2010
|
181
|
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
|
BLOOD
|
2016
|
178
|
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
|
JOURNAL OF CLINICAL INVESTIGATION
|
2016
|
178
|
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
|
IMMUNITY
|
2016
|
176
|
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
|
CLINICAL CANCER RESEARCH
|
2011
|
174
|
Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
|
LEUKEMIA
|
2016
|
172
|
A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
|
BLOOD
|
2012
|
172
|
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
|
JOURNAL OF CLINICAL ONCOLOGY
|
2016
|
171
|
CAR T cell immunotherapy for human cancer
|
SCIENCE
|
2018
|
164
|
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
|
BLOOD
|
2011
|
163
|
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
|
SCIENCE TRANSLATIONAL MEDICINE
|
2017
|
162
|
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
|
IMMUNOLOGICAL REVIEWS
|
2015
|
162
|
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
|
MOLECULAR THERAPY
|
2013
|
159
|
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
|
CANCER CELL
|
2015
|
158
|
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
|
SCIENCE TRANSLATIONAL MEDICINE
|
2015
|
155
|
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
|
SCIENCE TRANSLATIONAL MEDICINE
|
2014
|
153
|
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
|
BLOOD
|
2013
|
153
|
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
|
BLOOD
|
2014
|
151
|
Driving CAR T-cells forward
|
NATURE REVIEWS CLINICAL ONCOLOGY
|
2016
|
149
|
In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB)
|
CANCER RESEARCH
|
2011
|
145
|
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
|
HUMAN GENE THERAPY
|
2012
|
143
|
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression
|
CANCER RESEARCH
|
2011
|
143
|
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
|
MOLECULAR THERAPY
|
2017
|
142
|
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|
BLOOD
|
2016
|
141
|
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
|
NATURE MEDICINE
|
2015
|
141
|
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
|
CLINICAL CANCER RESEARCH
|
2014
|
141
|
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
|
CLINICAL CANCER RESEARCH
|
2017
|
139
|
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
|
NATURE MEDICINE
|
2018
|
138
|
The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
|
CANCER IMMUNOLOGY RESEARCH
|
2015
|
137
|
Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies
|
CANCER RESEARCH
|
2015
|
134
|
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
|
BLOOD
|
2012
|
134
|
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
|
CANCER DISCOVERY
|
2017
|
127
|
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
|
IMMUNITY
|
2016
|
127
|
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|
BLOOD
|
2017
|
124
|
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
|
JOURNAL OF CLINICAL INVESTIGATION
|
2016
|
123
|
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
|
CANCER IMMUNOLOGY RESEARCH
|
2016
|
117
|
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
|
CANCER RESEARCH
|
2015
|
115
|
Novel immunotherapies in lymphoid malignancies
|
NATURE REVIEWS CLINICAL ONCOLOGY
|
2016
|
114
|
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
|
CANCER IMMUNOLOGY RESEARCH
|
2013
|
112
|
Tandem CAR T cells targeting HER2 and IL13R alpha 2 mitigate tumor antigen escape
|
JOURNAL OF CLINICAL INVESTIGATION
|
2016
|
111
|
Cancer immunotherapy: harnessing the immune system to battle cancer
|
JOURNAL OF CLINICAL INVESTIGATION
|
2015
|
111
|
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
|
CANCER IMMUNOLOGY RESEARCH
|
2014
|
111
|
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
|
BLOOD
|
2016
|
108
|
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
|
CANCER RESEARCH
|
2016
|
106
|
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
|
BLOOD
|
2016
|
106
|
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
|
CANCER RESEARCH
|
2015
|
105
|
ICOS-based chimeric antigen receptors program bipolar T(H)17/T(H)1 cells
|
BLOOD
|
2014
|
105
|
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
|
CANCER DISCOVERY
|
2016
|
104
|
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe
|
TRENDS IN MOLECULAR MEDICINE
|
2012
|
104
|
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA(+) Liver Metastases
|
CLINICAL CANCER RESEARCH
|
2015
|
103
|
Chimeric Antigen Receptor Therapy
|
NEW ENGLAND JOURNAL OF MEDICINE
|
2018
|
102
|
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
|
CANCER RESEARCH
|
2015
|
102
|
Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template
|
SCIENCE TRANSLATIONAL MEDICINE
|
2015
|
101
|
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
|
CLINICAL CANCER RESEARCH
|
2016
|
97
|
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
|
HUMAN GENE THERAPY
|
2011
|
97
|
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
|
BLOOD
|
2017
|
96
|
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
|
JOURNAL OF CLINICAL ONCOLOGY
|
2017
|
95
|
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
|
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
|
2016
|
94
|
Engineering CAR-T cells: Design concepts
|
TRENDS IN IMMUNOLOGY
|
2015
|
91
|
Global Manufacturing of CAR T Cell Therapy
|
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
|
2017
|
90
|
Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies
|
CANCER RESEARCH
|
2011
|
88
|
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
|
BLOOD
|
2015
|
87
|
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
|
CANCER RESEARCH
|
2014
|
87
|
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
|
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
|
2016
|
86
|